Back to top

Allscripts Wins a Major Client

Read MoreHide Full Article

Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) , a leading player in the health care information technology (HCIT) market, recently announced that ProMedica has adopted the dbMotion interoperability system to build a base for population health management and improve its Accountable Care Organization.

Allscripts’ dbMotion will permit ProMedica to manage data from inpatient, outpatient and other sources. The purpose will be to engage in timely analysis and delivery of information within the Accountable Care Organization. dbMotion permits effective feedback to caregivers based on actionable data.

ProMedica, based in Toldeo, Ohio, is a non-profit healthcare entity with almost 1,700 doctors. It has 11 hospitals and over 310 medical establishments providing a wide range of medical care. ProMedica owns a health insurance company, Paramount.    

We are of the opinion that acute and ambulatory care will continue to converge in the future. In addition, Allscripts is positioned to provide integrated clinical applications for health care providers to satisfy their requirements and eventually comply with an outcome-based reimbursement system.

As a potential takeover target, Allscripts presents a lucrative opportunity for firms seeking entry into the HCIT industry. It has a wide user base and enjoys many opportunities vis-à-vis its peers. Its mergers with Misys and Eclipsys have expanded opportunities and reach in practice management (PM) and Electronic Health Record (EHR) markets substantially and increased cross-selling opportunities. We believe that Allscripts is well positioned in the fast growing business of selling EHR to physician practices as well as inpatient settings.

The HCIT market is competitive and price sensitive. Among others, Allscripts faces strong competition from Cerner Corporation (CERN - Free Report) , Quality Systems Inc. (QSII - Free Report) and Athenahealth, Inc. (ATHN - Free Report) . Allscripts carries a Zacks Rank #3 (Hold).

More from Zacks Analyst Blog

You May Like